Skip to main content
Premium Trial:

Request an Annual Quote

BioGenex Takes Over Support for Xmatrx Platform Following End of Abbott Partnership

NEW YORK (GenomeWeb News) – BioGenex and Abbott Molecular today announced that BioGenex will take over direct sales and support responsibility for the co-branded Xmatrx instruments, auto FISH reagents, and consumables.

The two firms had a "long and successful collaboration and partnership," said BioGenex, centered on BioGenex's Xmatrx platform, and in 2009 extended an assay deal to market the Xmatrx platform for the automation of Abbott's FISH product line.

Xmatrx FISH, BioGenex said, allows for the walk-away automation of all assay steps necessary to perform Abbott's FISH test, from baking to final cover slip. BioGenex will now support current Xmatrx customers.

Based on individual customer requests, the Fremont, Calif.-based company will also enable the platform to perform other slide-based assays, such as immunohistochemistry, in situ hybridization, and microRNA assays. BioGenex's Xmatrx Elite system comprises a platform for full automation of any slide-based assay, the firm said.

"Abbott and BioGenex are working closely and are committed to ensure seamless transition," BioGenex CEO Krishan Kalra said in a statement. "Hospitals, labs, and research institutions that use Xmatrx can be assured that they will get best in class service and support."

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.